Lexicon Pharmaceuticals, Inc. (LXRX) stock
LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.72−0.06 (-3.37%)
Close on Nov 18, 2026Market cap $765.32MP/E –Yield –
Lexicon Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Lexicon Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$54.50M. For fiscal 2025 it was -$48.91M. The highest annual figure on record is $141.45M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$48.91M | – |
| FY2024 | Dec 31, 2024 | -$197.12M | – |
| FY2023 | Dec 31, 2023 | -$171.75M | – |
| FY2022 | Dec 31, 2022 | -$100.76M | – |
| FY2021 | Dec 31, 2021 | -$87.09M | – |
| FY2020 | Dec 31, 2020 | -$47.80M | -133.8% |
| FY2019 | Dec 31, 2019 | $141.45M | – |
| FY2018 | Dec 31, 2018 | -$103.28M | – |
| FY2017 | Dec 31, 2017 | -$130.62M | – |
| FY2016 | Dec 31, 2016 | -$127.17M | -8762.9% |
| FY2015 | Dec 31, 2015 | $1.47M | – |
| FY2014 | Dec 31, 2014 | -$100.37M | – |
| FY2013 | Dec 31, 2013 | -$102.37M | – |
| FY2012 | Dec 31, 2012 | -$108.42M | – |
| FY2011 | Dec 31, 2011 | -$114.10M | – |
| FY2010 | Dec 31, 2010 | -$95.72M | – |
| FY2009 | Dec 31, 2009 | -$89.96M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$26.54M | -810.4% |
| Q1 FY2026 | Mar 31, 2026 | -$996.00K | – |
| Q4 FY2025 | Dec 31, 2025 | -$14.78M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.19M | – |
| Q2 FY2025 | Jun 30, 2025 | $3.74M | – |
| Q1 FY2025 | Mar 31, 2025 | -$25.68M | – |
| Q4 FY2024 | Dec 31, 2024 | -$32.74M | – |
| Q3 FY2024 | Sep 30, 2024 | -$63.69M | – |
| Q2 FY2024 | Jun 30, 2024 | -$55.35M | – |
| Q1 FY2024 | Mar 31, 2024 | -$45.33M | – |
| Q4 FY2023 | Dec 31, 2023 | -$46.74M | – |
| Q3 FY2023 | Sep 30, 2023 | -$49.63M | – |
| Q2 FY2023 | Jun 30, 2023 | -$44.24M | – |
| Q1 FY2023 | Mar 31, 2023 | -$31.14M | – |
| Q4 FY2022 | Dec 31, 2022 | -$30.28M | – |
| Q3 FY2022 | Sep 30, 2022 | -$23.10M | – |
| Q2 FY2022 | Jun 30, 2022 | -$24.01M | – |
| Q1 FY2022 | Mar 31, 2022 | -$23.38M | – |
| Q4 FY2021 | Dec 31, 2021 | -$25.33M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.96M | -126.5% |
| Q2 FY2021 | Jun 30, 2021 | -$17.96M | – |
| Q1 FY2021 | Mar 31, 2021 | -$20.84M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.46M | – |
| Q3 FY2020 | Sep 30, 2020 | $86.68M | -61.4% |
| Q2 FY2020 | Jun 30, 2020 | -$64.58M | – |
| Q1 FY2020 | Mar 31, 2020 | -$62.44M | – |
| Q4 FY2019 | Dec 31, 2019 | -$47.22M | – |
| Q3 FY2019 | Sep 30, 2019 | $224.68M | – |
| Q2 FY2019 | Jun 30, 2019 | -$18.55M | – |
| Q1 FY2019 | Mar 31, 2019 | -$17.47M | – |
| Q4 FY2018 | Dec 31, 2018 | -$12.37M | – |
| Q3 FY2018 | Sep 30, 2018 | -$22.93M | – |
| Q2 FY2018 | Jun 30, 2018 | -$30.27M | – |
| Q1 FY2018 | Mar 31, 2018 | -$37.71M | – |
| Q4 FY2017 | Dec 31, 2017 | -$29.02M | – |
| Q3 FY2017 | Sep 30, 2017 | -$28.61M | – |
| Q2 FY2017 | Jun 30, 2017 | -$33.49M | – |
| Q1 FY2017 | Mar 31, 2017 | -$39.51M | – |
| Q4 FY2016 | Dec 31, 2016 | -$31.33M | – |
| Q3 FY2016 | Sep 30, 2016 | -$34.93M | – |
See a number that looks wrong?